Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16570183 | 1.00 | L3MBTL3 (0.40) | L3MBTL3KDM1AMAOAMAOBKMT2A | |
| SCHEMBL21464535 | 0.88 | L3MBTL3 (0.50) | L3MBTL3KDM1AMAOAMAOBL3MBTL1 | |
| SCHEMBL2883532 | 0.88 | L3MBTL3 (0.50) | L3MBTL3KDM1AMAOAMAOBL3MBTL1 | |
| SCHEMBL2883536 | 0.88 | L3MBTL3 (0.50) | L3MBTL3KDM1AMAOAMAOBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL3404368 | 0.86 | L3MBTL3 (0.49) | L3MBTL3KDM1AMAOAMAOBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL3427002 | 0.86 | L3MBTL3 (0.49) | L3MBTL3KDM1AMAOAMAOBL3MBTL1 | |
| SCHEMBL2743260 | 0.85 | L3MBTL3 (0.40) | L3MBTL3KDM1AALDH1A1LMNAL3MBTL1 | |
| SCHEMBL24629710 | 0.83 | L3MBTL3 (0.39) | L3MBTL3KDM1AMAOAMAOBKMT2A | |
| SCHEMBL28684039 | 0.82 | ALDH1A1 (0.36) | KMT2AALDH1A1LMNAL3MBTL1JAK1 | |
| SCHEMBL29163767 | 0.82 | KMT2A (0.34) | L3MBTL3KMT2AALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | L3MBTL3 3001/4885KDM1A 1823/4885MAOA 2828/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | L3MBTL3 1889/4885KDM1A 1518/4885MAOA 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.